YD Bio Limited Ordinary Shares

YD Bio Limited (NASDAQ: YDES - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $5.68 and traded as high as $6.15. YD Bio shares last traded at $6.04, with a volume of 47,156 shares changing hands. Wall Street Analyst Weigh In

TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic innovations, today announced a strategic collaboration with EG BioMed Co., Ltd., a Taiwan registered company and an affiliate of YD Bio (“EG BioMed”), and digital health provider JoiiUp. The partnership integrates an AI Cancer Risk Assessment (the “Assessment”), jointly develope…

YD Bio Limited (NASDAQ: YDES - Get Free Report) was the recipient of a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 177,332 shares, a growth of 312.8% from the September 15th total of 42,960 shares. Based on an average daily trading volume, of 728,505

TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd.

YD Bio Limited (NASDAQ: YDES - Get Free Report)'s share price dropped 4.4% during mid-day trading on Wednesday. The stock traded as low as $6.80 and last traded at $7.2760. 68,234 shares changed hands during mid-day trading, a decline of 52% from the average daily volume of 141,640 shares. The stock had previously closed at $7.61.

YD Bio Limited (NASDAQ: YDES - Get Free Report) was the target of a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 42,960 shares, an increase of 223.2% from the August 31st total of 13,293 shares. Based on an average daily trading volume, of 619,936

TAIPEI, Taiwan, Aug. 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced its financial results for the six months ended June 30, 2026.

TAIPEI, Taiwan, Aug. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced the publication of a peer-reviewed review article in Nutrients, an international open-access journal published by MDPI (Multidisciplinary Digital Publishing Institute). The article, titled “Beyond Bone Health: Exploring the ‘Heart–Brain–Bone' Axis Modulated b…

Arbutus Biopharma (NASDAQ: ABUS - Get Free Report) and YD Bio (NASDAQ: YDES - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation. Profitability This table compares Arbutus Biopharma and